help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in AJRCCM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singer, M.
American Journal of Respiratory and Critical Care Medicine Vol 176. pp. 733-734, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200707-964ED


Editorials

Powering Up Failed Organs

Mervyn Singer, M.D., F.R.C.P.

Wolfson Institute for Biomedical Research and Department of Medicine, University College London, London, United Kingdom

The answer, the answer, the answer. What is the answer? ... In that case, what is the question?

—Gertrude Stein (1874–1946), on her deathbed

It's the simple questions that are often the hardest to answer, and that's assuming they're addressed in the first place. While "interleukin 2007" or any other novel mediator, gene, signaling protein, or enzyme may hold the key to the universe this month, it is likely to be supplanted by the newest "molecule on the block." Few of these, however, stand the test of time and achieve their place in the pantheon of great molecules. To aid our understanding of the big picture, we need to solve fundamental conundrums surrounding disease processes. This should then improve the targeting and timing of therapeutic interventions, both new and established. One such vital question that requires unraveling is how organs fail after sepsis and other acute inflammatory insults. Another equally important poser is how they recover.

Energy and persistence conquer all things.

—Benjamin Franklin (1706–1790)

Two remarkable features of sepsis-induced multiorgan failure are the absence of significant cell death in most affected organs (1) and the ability for these failed organs, even those with poor regenerative capacity, to recover so well that surviving patients rarely require lifelong organ support (2). How can these findings be reconciled into a paradigm that explains functional failure in the face of relative histologic normality? One attractive hypothesis is that multiorgan dysfunction represents an adaptive metabolic shutdown consequent to a progressive decrease in energy availability (3). Mitochondria, the cellular power reactors predominantly responsible for ATP production in most body cell types, are clearly affected by the septic process. Direct inhibition or damage of the electron transport chain by nitric oxide and other reactive species, diminished respiratory enzyme activity from altered hormonal stimulation (e.g., the sick euthyroid syndrome), and decreased mitochondrial protein turnover from down-regulated gene expression will contribute to an inability to fuel usual cellular processes during prolonged sepsis (47). If these processes attempt to continue functioning normally in the face of an inadequate energy supply, ATP levels will fall below the threshold that triggers cell death pathways. Because this does not appear to happen, a metabolic shutdown process akin to hibernation or estivation can be invoked (3).

Courage consists in the power of self-recovery.

—Ralph Waldo Emerson (1803–1882)

Assuming the validity of this hypothesis, recovery of organ function is predicated on restoration of normally functioning mitochondria. This process of mitochondrial biogenesis is triggered by nuclear transcription factors and coactivators that, in turn, are under regulatory control by various hormones and mediators (8). Piantadosi and colleagues have previously demonstrated oxidative damage to mitochondria yet minimal cell death in an endotoxic animal model (5), and an increase in mitochondrial biogenesis preceding the recovery phase. They continue their work with a new study in this issue of the Journal (pp. 768–777) (Haden and colleagues [9]). Using a long-term bacterial peritonitis model in mice, they found an increase in mitochondrial bioenergetic activity, peaking at 2 to 3 days post-insult, with consequent clinical and metabolic recovery. Concurrent with these changes, they also recorded activation of prosurvival antiapoptotic kinases and decreased expression of the mitochondrial biogenesis suppressor protein RIP140. This suggests strongly that there is an effective and integrated survival network in the surviving animals.

Future studies must crucially address the following points: (1) to determine whether changes in mitochondrial function are indeed causative of both organ "failure" and recovery after sepsis, rather than being mere epiphenomena; (2) to see whether this "survival network" is underexpressed in nonsurvivors; and (3) to determine whether these findings can be translated to humans. Preliminary data that we have accumulated in septic patients suggest that all of these may indeed be valid. However, confirmation will be both scary and exciting. If patients are indeed predetermined to live or die, are we, with current clinical practice, simply prolonging death in those destined to die, while saving those who would live unless an iatrogenic mishap befalls them? On a positive note, confirmation could promote new therapeutic strategies, either protecting mitochondria against inhibition and damage in the first place or accelerating biogenesis to stimulate recovery, thus thwarting nature by confounding the prediction of nonsurvival (10).

Of note, the mitochondrial biogenesis story has implications far removed from "merely" sepsis and organ failure. Decreased mitochondrial turnover has been invoked in the development of the metabolic syndrome (11) and in carcinogenesis (12). A further, more cautionary, aspect to be aware of is the potent ability of bacteriostatic antibiotics to inhibit mitochondrial biogenesis (13, 14). Perhaps this is not so surprising in view of the evolutionary link between bacteria and mitochondria highlighted by Margulis' endosymbiotic theory (15). Should we be assessing the clinical significance of prolonged treatment durations in delaying recovery from organ failure? Another consideration is the role of nitric oxide in stimulating mitochondrial biogenesis (16); this molecule is considered by many to be "evil" in sepsis. Attempts to scavenge NO or decrease its production may prove beneficial in the early septic shock phase but possibly detrimental if continued for too long.

Haden and colleagues (9) have made an important contribution to understanding pathophysiological mechanisms in sepsis, in part because of their study design. We would have been none the wiser from a short-term, large-hit model that would have excluded detection of this potentially crucial recovery mechanism, which lends itself to possible intervention. In addition, their attempts to correlate mitochondrial recovery with functional changes and clinical improvement lend further support to the significance of their findings. This work has reinforced the link between energy perturbation and organ failure and suggests that new strategies for preserving or restoring mitochondrial function will hold the key to "power up" failed organs in patients with sepsis.

FOOTNOTES

Conflict of Interest Statement: M.S. has no financial relationship with a commercial entity that has an interest in the subject of this manuscript.

REFERENCES

  1. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230–1251.[CrossRef][Medline]
  2. Noble JS, MacKirdy FN, Donaldson SI, Howie JC. Renal and respiratory failure in Scottish ICUs. Anaesthesia 2001;56:124–129.[CrossRef][Medline]
  3. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004;364:545–548.[CrossRef][Medline]
  4. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219–223.[CrossRef][Medline]
  5. Suliman HB, Welty-Wolf KE, Carraway M, Tatro L, Piantadosi CA. Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. Cardiovasc Res 2004;64:279–288.[Abstract/Free Full Text]
  6. Goglia F, Moreno M, Lanni A. Action of thyroid hormones at the cellular level: the mitochondrial target. FEBS Lett 1999;452:115–120.[CrossRef][Medline]
  7. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK: Inflammation and Host Response to Injury Large Scale Collaborative Research Program, et al. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032–1037.[CrossRef][Medline]
  8. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta 2002;1576:1–14.[Medline]
  9. Haden DW, Suliman HB, Carraway MS, Welty-Wolf KE, Ali AS, Shitara H, Yonekawa H, Piantadosi CA. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis. Am J Respir Crit Care Med 2007;176:768–777.[Abstract/Free Full Text]
  10. Protti A, Singer M. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. Crit Care 2006;10:228.[CrossRef][Medline]
  11. Nisoli E, Clementi E, Carruba MO, Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 2007;100:795–806.[Abstract/Free Full Text]
  12. Mazzanti R, Giulivi C. Coordination of nuclear- and mitochondrial-DNA encoded proteins in cancer and normal colon tissues. Biochim Biophys Acta 2006;1757:618–623.[Medline]
  13. Riesbeck K, Bredberg A, Forsgren A. Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob Agents Chemother 1990;34:167–169.[Abstract/Free Full Text]
  14. McKee EE, Ferguson M, Bentley AT. Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006;50:2042–2049.[Abstract/Free Full Text]
  15. Margulis L. Symbiosis in cell evolution: microbial communities in the Archean and Proterozoic eons. New York: W.H. Freeman and Co; 1993.
  16. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003;299:896–899.[Abstract/Free Full Text]

Related articles in AJRCCM:

Mitochondrial Biogenesis Restores Oxidative Metabolism during Staphylococcus aureus Sepsis
Douglas W. Haden, Hagir B. Suliman, Martha Sue Carraway, Karen E. Welty-Wolf, Abdelwahid S. Ali, Hiroshi Shitara, Hiromichi Yonekawa, and Claude A. Piantadosi
AJRCCM 2007 176: 768-777. [Abstract] [Full Text]  




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in AJRCCM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singer, M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society